If you do not choose someone in advance and there is a time you are unable to make your own decisions, there are state laws that help your healthcare providers determine who can make those decisions for you. You can give specific instructions, general guidance, or just say you want to decide for you and trust the person to do what is in your best interests at the time. When you chose someone to help you, you are also able to tell them what is important to you, about the kind of care you think is important or what they’d like to think about if they have to make a decision for you. These statements are referred to by different names, e.g., a durable power of attorney, healthcare proxy, or a designation of health agent. Whatever your stage of life, it is a good idea to think about who you would like to make decisions for you if you are unable to make decisions for yourself. Designation of an Agent for Healthcare Decisions in your StateĮvery state allows you to choose someone to make decisions about your healthcare when you are not able to make decisions for yourself. The best solution is if you spend a significant amount of time in more than one state, you should complete the advance directives for all the states you spend a significant amount of time in. Some states do honor advance directives from another state others will honor out-of-state advance directives as long as they are similar to the state’s own law and some states do not have an answer to this question. ![]() In January 2022, the FDA also expanded the use of remdesivir to treat non-hospitalized patients with mild-to-moderate COVID-19 who are at high risk for progression to severe disease.One state’s advance directive does not always work in another state. On December 21, 2021, the indication expanded to include the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. Remdesivir was also approved by the European Commission on Jfor the treatment of COVID-19 in adults and adolescents with pneumonia requiring supplemental oxygen. Remdesivir in combination with baricitinib for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on November 19, 2020. Remdesivir is currently marketed under the trademark name VEKLURY® by Gilead Sciences Inc. ![]() The FDA subsequently granted full approval for remdesivir as a COVID-19 treatment on October 22, 2020, while simultaneously updating the EUA to cover those patients not included under the approved indication. Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV, and has been investigated in multiple COVID-19 clinical trials.īased on aggregate data, remdesivir was granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020. Remdesivir activity against the Coronaviridae family was first demonstrated in 2017, leading to considerable interest in remdesivir as a possible treatment for COVID-19. Broad antiviral activity of remdesivir is suggested by its mechanism of action, and to date, it has demonstrated in vitro activity against the Arenaviridae, Flaviviridae, Filoviridae, Paramyxoviridae, Pneumoviridae, and Coronaviridae viral families. ![]() Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS) COVID-19 can be fatal.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |